Viewing nowIbandronate Tablets (Sodium Ibandronate Hydrate)
Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

MFDS item code 201205830 · Notified 2012.06.22 · Insurance code 656003260
Treatment of osteoporosis in postmenopausal women
This medication is used to treat osteoporosis commonly occurring in postmenopausal women. Osteoporosis is a condition where bones become weak and can break easily. This drug strengthens bones and reduces the risk of fractures. Regular use can improve bone density and help maintain a healthy lifestyle. Therefore, it is effective for the treatment of postmenopausal osteoporosis.
Take 1 tablet once a month, regularly on the same day each month in the morning, with plenty of water, at least 1 hour before consuming food, beverages (other than water), or other oral medications or dietary supplements (including calcium): - This medicine should be swallowed with a sufficient amount of water (180-240ml) while standing or sitting upright, and you must not lie down for 60 minutes after taking it. - Mineral water may reduce the absorption of this medicine, so take it with plain water. - To avoid esophageal ulcers, do not chew or suck the tablet. If a patient forgets to take a dose on the regularly scheduled day: - If 8 days or more remain until the next regularly scheduled dose, take 1 tablet the morning after realizing that the dose was missed, and thereafter take 1 tablet each month on the previously scheduled day. - If 7 days or fewer remain until the next regularly scheduled dose, take 1 tablet on the next regularly scheduled day, and thereafter continue taking 1 tablet each month on the previously scheduled day. - Do not take 2 tablets in the same week. Patients whose dietary intake is inadequate should supplement with calcium or vitamin D, etc. Patients with hepatic impairment No dosage adjustment is necessary. Patients with renal impairment No dosage adjustment is necessary for patients with mild or moderate renal impairment whose creatinine clearance is 30mL/min or more. As clinical experience is insufficient in patients with creatinine clearance below 30mL/min, administration of this medicine is not recommended. Older adults No dosage adjustment is necessary.
Efficacy and safety in children 18 years of age or younger have not been studied.
This medication should not be used in certain patients. For example, it should not be administered to patients who have allergies to this medication or its components, untreated hypocalcemia, patients who cannot sit or stand upright for more than 60 minutes, and patients with esophageal issues that impede the passage of food. Additionally, this medication contains lactose and should not be used by patients with lactose intolerance or certain genetic conditions. Caution is necessary for patients with severe renal impairment. Side effects such as indigestion, nausea, abdominal pain, diarrhea, headache, muscle pain, joint pain, and rash may occur during the course of treatment. Particularly during initial administration, influenza-like symptoms may appear temporarily and are mostly mild and resolve without treatment. This medication can irritate the gastrointestinal mucosa, potentially leading to severe complications such as esophagitis, esophageal ulcers, and esophageal erosions, so the correct usage should be strictly followed. If difficulty swallowing or chest pain occurs, discontinue use immediately and consult a physician. Being a bisphosphonate, rare side effects such as osteonecrosis of the jaw or external auditory canal osteonecrosis have been reported, so a dental examination before any dental treatment is advisable, and excessive dental treatments during therapy should be avoided. Significant bone, joint, or muscle pain may occur, and rarely, atypical fractures may occur in the femur and other bones, so inform a doctor if these symptoms appear. This medication may interfere with absorption when taken with food or products containing calcium, aluminum, magnesium, or iron, so it should not be taken with such food or medications for at least 1 hour after consumption. It is safe to avoid this medication in pregnant or breastfeeding women. The safety and efficacy in children or adolescents under 18 years have not been established. Overdose may lead to gastrointestinal discomfort or hypocalcemia, so caution is needed with dosage, and do not induce vomiting; remain upright. This medication should be kept out of the reach of children, and unused drugs should be disposed of properly to prevent environmental contamination.
Dyspepsia, nausea, abdominal pain, diarrhea, bloating, gastroesophageal reflux disease, headache, influenza-like illness, fatigue, myalgia, arthralgia, rash, gastritis, esophagitis, muscle cramps, musculoskeletal pain, musculoskeletal stiffness, dysphagia, vomiting, esophageal ulcer, stricture, dizziness, low back pain, duodenitis, hypersensitivity reactions, angioedema, facial edema, urticaria, uveitis, scleritis, osteonecrosis of the jaw and external ear, anaphylactic reaction, shock, allergic reactions, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical periprosthetic and subtrochanteric femoral fractures, atypical fractures of the iliac bone, visual disturbances, weakness, pruritus
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a tightly closed container to prevent air and moisture from entering. It is recommended to store at room temperature between 1 and 30 degrees Celsius.
White to almost white oval film-coated tablets
1 tablet/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowIbandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.